Acquisition Announced

UCB acquisition of Candid Therapeutics

US$2.2bn consideration

Announced 4 May 2026

Advisers

Target
Candid Therapeutics
Acquirer
UCB
Target based in
United States
Buyer based in
Belgium
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.